ENDOPIN - BTB Therapeutics
Latest Information Update: 03 Jun 2024
At a glance
- Originator Kyoto University
- Developer BTB Therapeutics; Kyoto University
- Class Analgesics
- Mechanism of Action Alpha 2b adrenergic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Postoperative pain